Find It Endometrial panel references

 

Ref No.               1

Title                     Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma.

Journal              Am J Surg Pathol. 2013; 37:874-881.

PubMed ID:      23629444

 

Ref No.               2

Title                     Histotype-genotype correlation in 36 high-grade endometrial carcinomas.

Journal              Am J Surg Pathol. 2013; 37: 1421-1432.

PubMed ID:      24076778

 

Ref No.               3

Title                     Integrated genomic characterization of endometrial carcinoma.

Journal              Nature. 2013; 497: 67-73.

PubMed ID:      23636398

 

Ref No.               4

Title                     A clinically applicable molecular-based classification for endometrial cancers.

Journal              Br J Cancer. 2015; 113:299-310.

PubMed ID:      26172027

 

Ref No.               5

Title                     Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer.

Journal              Cancer 2017; 123(5): 802–813.

PubMed ID:      28061006

 

Ref No.               6

Title                     Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.

Journal              Ann Oncol. 2018 May 1; 29(5):1180-1188

PubMed ID:      29432521

 

Ref No.               7

Title                     Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment.

Journal              Gynecol Oncol. 2016; 143:46-53.

PubMed ID:      27421752

 

Ref No.               8

Title                     New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.

Journal              Gynecologic Oncology Research and Practice (2016) 3:14

PubMed ID:      27999680

 

Ref No.               9

Title                     Just how accurate are the major risk stratification systems for early-stage endometrial cancer?

Journal              Br J Cancer 2015; 112: 793–801.

PubMed ID:      25675149

 

Ref No.               10

Title                     DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer.    

Journal              Hum Mol Genet 2013; 22: 2820–2828.

PubMed ID:      23528559

 

Ref No.               11

Title                     Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication.

Journal              Genome Res 2014; 24: 1740–1750

PubMed ID:      25228659

 

Ref No.               12           

Title                     Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1.

Journal              JAMA Oncol 2015; 1: 1319–1323.

PubMed ID:      26181000

 

Ref No.               13

Title                     POLE proofreading mutations elicit an antitumor immune response in endometrial cancer.   

Journal              Clin Cancer Res 2015; 21: 3347–3355.

PubMed ID:      25878334

 

Ref No.               14

Title                     Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.      

Journal              Histopathology 2016; 68: 916–924.

PubMed ID:      26416160

 

Ref No.               15

Title                     Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.   

Journal              Oncoimmunology 2017; 6: e1264565.

PubMed ID:      28344870

 

Ref No.               16

Title                     Clinico pathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.             

Journal              Mod Pathol 2015; 28: 505–514.

PubMed ID:      25394778

 

Ref No.               17

Title                     Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’exons of TACSTD1.

Journal              Nat Genet 2009; 41: 112–117.

PubMed ID:      19098912

 

Ref No.               18

Title                     Novel implications in molecular diagnosis of Lynch syndrome.              

Journal              Gastroenterol Res Pract 2017; 2017: 2595098

PubMed ID:      28250766

 

Ref No.               19

Title                     Comprehensive analysis of hypermutation in human cancer.   

Journal              Cell 2017; 171: 1042–1056.e10.

PubMed ID:      29056344

 

Ref No.               20

Title                     The genetic landscape of endometrial clear cell carcinomas.   

Journal              J Pathol 2017 Oct; 243(2):230-241.

PubMed ID:      28718916

 

Ref No.               21

Title                     Molecular genetic heterogeneity in undifferentiated endometrial carcinomas.        

Journal              Mod Pathol 2016 Nov; 29 (11):1390-1398

PubMed ID:      27491810

 

Ref No.               22

Title                     Frequent mismatch repair protein deficiency in mixed endometrioid and clear cell carcinoma of the endometrium.                 

Journal              Int J Gynecol Pathol 2017; 36: 555–561.

PubMed ID:      28114191

 

Ref No.               23

Title                     Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.                   

Journal              Oncoimmunology 2017; 6: e1264565

PubMed ID:      28344870

 

Ref No.               24

Title                     Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts.              

Journal              Clin Cancer Res 2016; 22: 4215–4224.

PubMed ID:      27006490

 

Ref No.               25

Title                     A clinically applicable molecular-based classification for endometrial cancers.     

Journal              Br J Cancer 2015; 113: 299–310.

PubMed ID:      26172027

 

Ref No.               26

Title                     Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.       

Journal              Gynecol Oncol 2017; 146: 588–595

PubMed ID:      28709704

 

Ref No.               27

Title                     Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts.              

Journal              Clin Cancer Res 2016; 22: 4215–4224.

PubMed ID:      27006490

 

Ref No.               28

Title                     Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.             

Journal              Mod Pathol 2015; 28: 836–844.

PubMed ID:      25720322

 

Ref No.               29

Title                     Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.

Journal              Clin Cancer Res. 2016 Aug 15;22(16):4215-24.

PubMed ID:      27006490

 

Ref No.               30

Title                     The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.

Journal              J Pathol 2018; 244: 538–549.

PubMed ID:      29344951

 

Ref No.               31

Title                     PORTEC-4a: Randomised Trial of Standard or Molecular Profile-Based Recommendation for Radiotherapy after Surgery for Women with Early Stage Endometrial Cancer;

Journal              2016 Jun 01. [Accessed 20 December 2017]. Available from: https://www.isrctn.com/ISRCTN11659025

 

Ref No.               32

Title                     Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC4a trial. 

Journal              Gynecologic Oncology 151 (2018) 69–75.

PubMed ID:      30078506

 

Ref No.               33

Title                     Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 Study.              

Journal              J Clin Oncol 2017; 35: 2535–2541.          

PubMed ID:      28489510

 

Ref No.               34

Title                     Prognostic significance of pole proofreading mutations in endometrial cancer.      

Journal              J. Natl Cancer Inst. 2015; 107; 402

PubMed ID:      25505230

 

Ref No.               35
Title                     POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.                
Journal              Gynecol. Oncol. 2014; 134; 15–19.          
PubMed ID:      24844595

 

Ref No.               36

Title                     Endometrial carcinomas with pole exonuclease domain mutations have a favorable prognosis.            

Journal              Clin. Cancer Res. 2016; 22; 2865–2873.

PubMed ID:      26763250

 

Ref No.               37

Title                     Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.     

Journal              J. Clin. Invest. 2016; 126; 2334–2340.

PubMed ID:      27159395

 

Ref No.               38

Title                     Regression of chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab.         

Journal              Clin. Cancer Res. 2016; 22; 5682–5687.

PubMed ID:      27486176

 

Ref No.               39

Title                     Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.               

Journal              J Natl Cancer Inst 2014; 106: pii: dju245.

PubMed ID:      25214561

 

Ref No.               40

Title                     CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.   

Journal              Mod Pathol 2017; 30: 1032–1041.

PubMed ID:      28281553

 

Ref No.               41

Title                     L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.  

Journal              Br J Cancer 2016; 115: 716–724.

PubMed ID:      27505134

 

Ref No.               42

Title                     Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients.           

Journal              Br J Cancer 2017; 117: 840–847.

PubMed ID:      28751757

 

Ref No.               43

Title                     Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.   

Journal              Mod Pathol 2016; 29: 174–181.

PubMed ID:      26743472

 

Ref No.               44

Title                     L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.    

Journal              Eur J Cancer 2014; 50: 2602–2610.

PubMed ID:      25126672

 

Ref No.               45

Title                     L1CAM in early-stage type endometrial cancer: results of a large multicentre evaluation.     

Journal              JNatl Cancer Inst 2013; 105: 1142–1150.

PubMed ID:      23781004

 

Ref No.               46

Title                     Review. Incorporation of molecular characteristics into endometrial cancer management.

Journal              Histopathology 2020, 76, 52–63.

PubMed ID:      31846532